Limited overall survival in patients with brain metastases from triple negative breast cancer

Breast Journal

Volumn 18, Issue 4, 2012, Pages 345-350

  Morris, Patrick G ^a   Murphy, Conleth G ^a   Mallam, Divya ^a   Accordino, Melissa ^a   Patil, Sujata ^b   Howard, Jane ^a   Omuro, Antonio ^b   Beal, Kathryn ^b   Seidman, Andrew D ^a   Hudis, Clifford A ^a   Fornier, Monica N ^a,c  

^a Department of Medicine   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

brain metastases; breast cancer; incidence; overall survival; recurrence patterns; triple negative

Indexed keywords

CYTARABINE; METHOTREXATE;

ADULT; AGED; ARTICLE; BRAIN DISEASE; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; LEPTOMENINGEAL DISEASE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; TRIPLE NEGATIVE BREAST CANCER;

AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MENINGEAL NEOPLASMS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84863723785     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2012.01246.x     Document Type: Article

References (31)

1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-74.
2. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
4. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
5. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2009; 28: 509-18.
6. American-Cancer-Society. Cancer Statistics 2009 Presentation. Available at: (accessed September 7, 2009), 2009.
7. Siziopikou KP, Cobleigh M,. The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007; 16: 104-7.
8. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-71.
9. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34.
10. Blanchard AA, Skliris GP, Watson PH, et al. Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch 2009; 454: 647-56.
11. Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol 2009; 20: 621-7.
12. Heitz F, Harter P, Lueck HJ, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 2009; 45: 2792-8.
13. Clarke M, Coates AS, Darby SC, et al. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. Lancet 2008; 371: 29-40.
14. Seidman AD,. Brain metastases from breast cancer. Clin Adv Hematol Oncol 2010; 8: 595-7.
15. Niwinska A, Murawska M, Pogoda K,. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 2010; 116: 4238-47.
16. Niwinska A, Murawska M, Pogoda K,. Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2009; 21: 942-8.
17. Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2010; 2010:29.
18. Graesslin O, Abdulkarim BS, Coutant C, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 2010; 28: 2032-7.
19. Murphy CG, Moynahan ME,. BRCA gene structure and function in tumor suppression: a repair-centric perspective. Cancer J 2010; 16: 39-47.
20. Gucalp A, Traina TA,. Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010; 16: 62-5.
21. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235-44.
22. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364: 205-14.
23. Fornier MN, Morris PG, Abbruzzi A, et al. A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol 2011; 22: 2575-81.
24. Labidi SI, Bachelot T, Ray-Coquard I, et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 2009; 9: 118-21.
25. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28: 3239-47.
26. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
27. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-9.
28. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2009;Abstract 1005.
29. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor 2-negative metastatic breast cancer. J Clin Oncol 2011; 29: 4286-93.
30. Murphy C, Nulsen B, Rump M, et al. Phase II trial of patupilone in patients (pts) with breast cancer brain metastases (BCBM) progressing or recurring after whole brain radiotherapy (WBXRT). ASCO Breast Cancer Symposium, San Francisco, CA, 8-10 Oct 2009 (abstract 234).
31. Lassman AB, Abrey LE, Shah GD, et al., Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 2006; 78: 255-60.